GSK (LON:GSK) Stock Passes Above Two Hundred Day Moving Average – Here’s Why

by · The Markets Daily

GSK plc (LON:GSK – Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 1,562.34 and traded as high as GBX 1,824. GSK shares last traded at GBX 1,812.50, with a volume of 7,323,830 shares.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Jefferies Financial Group upped their price objective on shares of GSK from GBX 2,000 to GBX 2,100 and gave the company a “buy” rating in a report on Monday, November 3rd. JPMorgan Chase & Co. boosted their target price on shares of GSK from GBX 1,400 to GBX 1,500 and gave the stock an “underweight” rating in a research report on Friday, November 7th. Shore Capital reaffirmed a “buy” rating and issued a GBX 2,100 price target on shares of GSK in a report on Monday, October 20th. Finally, Berenberg Bank lifted their price objective on shares of GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a research note on Monday, November 24th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of GBX 1,762.

Read Our Latest Report on GSK

GSK Stock Performance

The firm’s 50 day simple moving average is GBX 1,758.28 and its 200 day simple moving average is GBX 1,564.31. The firm has a market capitalization of £72.69 billion, a price-to-earnings ratio of 13.54, a PEG ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81.

GSK (LON:GSK – Get Free Report) last released its quarterly earnings data on Wednesday, October 29th. The company reported GBX 55 earnings per share for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Sell-side analysts forecast that GSK plc will post 175.980975 earnings per share for the current fiscal year.

About GSK

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

Featured Stories